Pulsatile ex vivo perfusion of human saphenous vein grafts under controlled pressure conditions increases MMP-2 expression

BioMedical Engineering Online

Volumn 10, Issue , 2011, Pages

  Dummler, Sara ^a   Eichhorn, Stefan ^a   Tesche, Christian ^a   Schreiber, Ulrich ^a   Voss, Bernhard ^a   Deutsch, Marcus André ^a   Hauner, Hans ^a   Lahm, Harald ^a   Lange, Rüdiger ^a   Krane, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atherosclerosis; Bypass Surgery; MMP; Perfusion; Pulsatile flow; vein graft

Indexed keywords

ATHEROSCLEROSIS; BYPASS-SURGERY; MMP; PERFUSION; VEIN GRAFTS;

BLOOD VESSELS; BROMINE COMPOUNDS; HEMODYNAMICS; HYDRODYNAMICS;

DISEASES;

GELATINASE A; MMP2 PROTEIN, HUMAN;

AGED; ARTERY; ARTICLE; CORONARY ARTERY DISEASE; FEMALE; GENETICS; HUMAN; IN VITRO STUDY; MALE; METABOLISM; PRESSURE; PULSATILE FLOW; SAPHENOUS VEIN; TRANSPLANTATION; TREATMENT FAILURE; UPREGULATION;

AGED; ARTERIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; PRESSURE; PULSATILE FLOW; SAPHENOUS VEIN; TRANSPLANTS; TREATMENT FAILURE; UP-REGULATION;

EID: 79960559610     PISSN: 1475925X     EISSN: 1475925X     Source Type: Journal    
DOI: 10.1186/1475-925X-10-62     Document Type: Article

References (37)

1. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998, 97:916-931.
2. Campeau L, Enjalbert M, Lespérance J, Bourassa MG, Kwiterovich P, Wacholder S, Sniderman A. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. New Engl J Med 1984, 311:1329-1332. 10.1056/NEJM198411223112101, 6333635.
3. Dashwood MR. Endothelin-1 and vein graft occlusion in patients undergoing bypass surgery. Eur J Clin Invest 2009, 39:78-87.
4. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996, 28:616-626.
5. Grondin CM, Campeau L, Lespérance J, Enjalbert M, Bourassa MG. Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation. Circulation 1984, 70:I208-1212.
6. Kloppenburg GT, Grauls GE, Bruggeman CA, Stassen FR. Adenoviral activin A expression prevents vein graft intimal hyperplasia in a rat model. Interact Cardiovasc Thorac Surg 2009, 8:31-34.
7. Gusic RJ, Myung R, Petko M, Gaynor JW, Gooch KJ. Shear stress and pressure modulate saphenous vein remodeling ex vivo. J Biochmech 2005, 38:1760-1769.
8. Thomas AC, Newby AC. Effect of Matrix Metalloproteinase-9 knockout on vein graft remodelling in mice. J Vasc Res 2010, 47:299-308. 10.1159/000265564, 2917759, 20016204.
9. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999, 282:2035-2042. 10.1001/jama.282.21.2035, 10591386.
10. Smith S, Austin S, Wesson GD, Moore CA. Calculation of wall shear stress in left coronary artery bifurcation for pulsatile flow using two-dimensional computational fluid dynamics. Conf Proc IEEE Eng Med Biol Soc 2006, 1:871-874.
11. Muto A, Model L, Ziegler K, Eghbalieh SD, Dardik A. Mechanisms of vein graft adaptation to the arterial circulation: insights into the neointimal algorithm and management strategies. Circ J 2010, 74:1501-1512. 10.1253/circj.CJ-10-0495, 20606326.
12. Doronzo G, Russo I, Mattiello L, Trovati M, Anfossi G. Homocysteine rapidly increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells. Role of phosphatidyl inositol 3-kinase and mitogen activated protein kinase pathways. Thromb Haemost 2005, 94:1285-1293.
13. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005, 85:1-31. 10.1152/physrev.00048.2003, 15618476.
14. Whatling C, McPheat W, Hurt-Camejo E. Matrix management: assigning different roles for MMP-2 and MMP-9 in vascular remodelling. Arterioscl Thromb Vasc Biol 2004, 24:10-11. 10.1161/01.ATV.0000100562.63144.C1, 14707036.
15. Wilson YG, Davies AH, Southgate K, Currie IC, Sheffield E, Baird RN, Lamont PM, Angelini GD. Vein quality influences neointimal hyperplasia in an organ culture model of human saphenous vein. Eur J Vasc Endovasc Surg 1997, 13(6):557-562. 10.1016/S1078-5884(97)80064-0, 9236708.
16. Berceli SA, Jiang Z, Klingman NV, Pfahnl CL, Abouhamze ZS, Frase CD, Schultz GS, Ozaki CK. Differential expression and activity of matrix metalloproteinases during flow-modulated vein graft remodeling. J Vasc Surg 2004, 39(5):1084-1090. 10.1016/j.jvs.2003.12.031, 15111865.
17. Patterson MA, Leville CD, Hower CD, Jean-Claude JM, Seabrook GR, Towne JB, Cambria RA. Shear force regulates matrix metalloproteinase activity in human saphenous vein organ culture. J Surg Res 2001, 95(1):67-72. 10.1006/jsre.2000.6045, 11120638.
18. Bernas T, Dobrucki J. Mitochondrial and Nonmitochondrial Reduction of MTT: Interaction of MTT with TMRE, JC-1, and NAO Mitochondrial Fluorescent Probes. Cytometry 2002, 47:236-242. 10.1002/cyto.10080, 11933013.
19. Burunova VV, Gisina AM, Kholodenko IV, Lupatov AY, Shragina OA, Yarygin KN. Standardization of Biochemical Profile of Mesenchymal Cell Materials by Probing the Level of Dehydrogenase Activity. Bull Exp Biol Med 2010, 149(4):497-501. 10.1007/s10517-010-0978-0, 21234451.
20. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, Gerlach RF, Tanus-Santos JE. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008, 198:320-331. 10.1016/j.atherosclerosis.2007.10.011, 18054360.
21. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, Cicero AF. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2004, 13:227-231.
22. Mavromatis K, Fukai T, Tate M, Chesler N, Ku DN, Galis ZS. Early effects of arterial hemodynamic conditions on human veins perfused ex vivo. Arterioscler Thromb Vasc Biol 2000, 20:1889-1895. 10.1161/01.ATV.20.8.1889, 10938008.
23. Tran-Son-Tay R, Hwang M, Garbey M, Jiang Z, Ozaki CK, Berceli SA. An experiment-based model of vein graft remodeling induced by shear stress. Ann Biomed Eng 2008, 36(7):1083-1091. Epub 2008 Apr 15, 10.1007/s10439-008-9495-y, 18415018.
24. Hilker M, Längin T, Hake U, Schmid FX, Kuroczynski W, Lehr HA, Oelert H, Buerke M. Gene expression profiling of human stenotic aorto-coronary bypass grafts by cDNA array analysis. Eur J Cardiothorac Surg 2003, 23:620-625. 10.1016/S1010-7940(03)00017-4, 12694787.
25. Marques FZ, Campain AE, Yang YH, Morris BJ. Meta-analysis of genome-wide gene expression differences in onset and maintenance phases of genetic hypertension. Hypertension 2010, 56:319-324. 10.1161/HYPERTENSIONAHA.110.155366, 20585107.
26. Puig O, Wang IM, Cheng P, Zhou P, Roy S, Cully D, Peters M, Benita Y, Thompson J, Cai TQ. Transcriptome profiling and network analysis of genetically hypertensive mice identifies potential pharmacological targets of hypertension. Physiol Genomics 2010, 42:24-32.
27. Jiang Z, Tao M, Omalley KA, Wang D, Ozaki CK, Berceli SA. Established neointimal hyperplasia in vein grafts expands via TGF-beta-mediated progressive fibrosis. Am J Physiol Heart Circ Physiol 2009, 297(4):H1200-1207. Epub 2009 Jul 17, 10.1152/ajpheart.00268.2009, 2770754, 19617405.
28. Miyakawa AA, Dallan LAO, Lacchini S, Borin TF, Krieger JE. Human saphenous vein organ culture under controlled hemodynamic conditions. Clinics 2008, 63:683-688. 10.1590/S1807-59322008000500018, 2664728, 18925330.
29. Saucy F, Probst H, Alonso F, Bérard X, Déglise S, Dunoyer-Geindre S, Mazzolai L, Kruithof E, Haefliger JA, Corpataux JM. Ex vivo pulsatile perfusion of human spahenous veins induces intimal hyperplasia and increased levels of the plasminogen activator inhibitor 1. Eur Surg Res 2010, 45:50-59. 10.1159/000318602, 20798546.
30. Porter KE, Nydahl S, Dunlop P, Varty K, Thrush AJ, London NJM. The development of an in vitro flow model of human saphenous vein graft intimal hyperplasia. Cardiovasc Res 1996, 31:607-614.
31. Paroz A, Probst H, Saucy F, Mazzolai L, Rizzo E, Ris HB, Corpataux JM. Comparison of morphological and functional alterations of human saphenous veins after seven and fourteen days of ex vivo perfusion. Eur Surg Res 2004, 36:274-281. 10.1159/000079912, 15359090.
32. Park H, Berzin I, De Luis J, Vunjak-Novakovic G. Evaluation of silicone tubing toxicity using tobacco BY2 culture. In Vitro Cell Dev Biol -Plant 2005, 41(4):555-560.
33. Rey J, Probst H, Mazzolai L, Bosman FT, Pusztaszeri M, Stergiopulos N, Ris HB, Hayoz D, Saucy F, Corpataux JM. Comparative assessment of intimal hyperplasia development after 14 days in two different experimental settings: tissue culture versus ex vivo continuous perfusion of human saphenous vein. J Surg Res 2004, 121:42-49. 10.1016/j.jss.2004.04.003, 15313374.
34. Labadie RF, Antaki JF, Williams JL, Katyal S, Ligush J, Watkins SC, Pham SM, Borovetz HS. Pulsatile perfusion system for ex vivo investigation of biochemical pathways in intact vascular tissue. Am J Physiol 1996, 270:H760-768.
35. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665. 10.1136/bmj.b1665, 2684577, 19454737.
36. Roth AG, Drescher D, Yang Y, Redmer S, Uhlig S, Arenz C. Potent and selective inhibition of acid sphingomyelinase by biphosphonates. Angew Chemie Int Ed Engl 2009, 48:7560-7563.
37. Zahler S, Liebl J, Fürst R, Vollmar AM. Anti-angiogenic potential of small molecular inhibitors of cyclin dependent kinases in vitro. Angiogenesis 2010, 13:239-249. 10.1007/s10456-010-9181-1, 20706783.